Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and effectiveness of RG1068 (synthetic human secretin) with MRCP in subjects with abnormalities of the pancreas.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Repligen Corporation
• Treatments: Secretin

Criteria

Inclusion Criteria:

• History of pancreatitis

• Medically stable

• Able to give informed consent

Exclusion Criteria:

• Prior history of pancreatic resection

• Prior history of pancreatic duct drainage procedure

• Presence of a pancreatic stent

• Unstable cardiovascular disease

• Any contraindication to MRI procedure

• Pregnancy